Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983282 | 0.92 | BCL2 (0.43) | BCL2EPHX2NR1H4AOC3PTGER4 | |
| SCHEMBL13992409 | 0.92 | ADRB1 (0.44) | EPHX2NR1H4PTGER4PTGER2ADRB1 | |
| SCHEMBL4939912 | 0.91 | PTGER4 (0.45) | PTGER4PTGER2ADRB1ADRB3 | |
| SCHEMBL13992388 | 0.90 | BCL2 (0.44) | BCL2EPHX2NR1H4AOC3CTSL | |
| SCHEMBL4941608 | 0.88 | PTGER4 (0.51) | PTGER4PTGER2HDAC1ADRB1ADRB3 | |
| SCHEMBL4938520 | 0.88 | PTGER4 (0.51) | PTGER4PTGER2CTSLCTSBCTSS | |
| SCHEMBL4943296 | 0.88 | PTGER4 (0.51) | PTGER4PTGER2 | |
| SCHEMBL4943525 | 0.88 | PTGER4 (0.51) | PTGER4PTGER2 | |
| SCHEMBL4937237 | 0.88 | ACACB (0.39) | PTGER4PTGER2 | |
| SCHEMBL4940816 | 0.86 | PTGER4 (0.53) | PTGER4PTGER2ADRB1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | claimed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| EP-1654219-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012232-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | PTGIR, HPGDS, PGF | BCL2 2481/4885EPHX2 514/4885NR1H4 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.